OBJECTIVE: To investigate longitudinal cognitive functioning in patients with brain tumor treated with modern highly conformal fractionated partial brain radiation therapy (RT). METHODS: Seventeen (of 22 initial consecutive patients) adults with primarily low-grade brain neoplasms who underwent either biopsy or tumor resection were tested at pre-RT baseline and at 3, 6, 12, and 24 months after baseline. Participants were classified as RT-treated nonprogressors (n = 12) or progressors (n = 3) based on serial follow-up structural imaging. Two patients received surgery only and served as controls to help minimize surgical, practice, test form, or other potential non-RT effects. Serial neuropsychological assessments were conducted using alternate forms of the Selective Reminding Test, 10/36 Spatial Recall Test, and Symbol Digit Modality Test (oral, written) as well as the Shipley Scale (baseline only), Wechsler Adult Intelligence Scale-Revised Digit Span, Trail Making Test, and the Symptom Checklist-90-Revised Global Severity Index scale. RESULTS: There was evidence of subtle attention and memory improvement in RT-treated nonprogressors throughout the 2-year period, with no evidence of cognitive decline. In contrast, patients with disease progression evidenced more substantial decline in memory and attention. CONCLUSIONS: Partial brain fractionated RT was not associated with adverse neuropsychological effects through the first 2 years following therapy.
OBJECTIVE: To investigate longitudinal cognitive functioning in patients with brain tumor treated with modern highly conformal fractionated partial brain radiation therapy (RT). METHODS: Seventeen (of 22 initial consecutive patients) adults with primarily low-grade brain neoplasms who underwent either biopsy or tumor resection were tested at pre-RT baseline and at 3, 6, 12, and 24 months after baseline. Participants were classified as RT-treated nonprogressors (n = 12) or progressors (n = 3) based on serial follow-up structural imaging. Two patients received surgery only and served as controls to help minimize surgical, practice, test form, or other potential non-RT effects. Serial neuropsychological assessments were conducted using alternate forms of the Selective Reminding Test, 10/36 Spatial Recall Test, and Symbol Digit Modality Test (oral, written) as well as the Shipley Scale (baseline only), Wechsler Adult Intelligence Scale-Revised Digit Span, Trail Making Test, and the Symptom Checklist-90-Revised Global Severity Index scale. RESULTS: There was evidence of subtle attention and memory improvement in RT-treated nonprogressors throughout the 2-year period, with no evidence of cognitive decline. In contrast, patients with disease progression evidenced more substantial decline in memory and attention. CONCLUSIONS: Partial brain fractionated RT was not associated with adverse neuropsychological effects through the first 2 years following therapy.
Authors: Adam Gerstenecker; Roy Martin; Daniel C Marson; Khurram Bashir; Kristen L Triebel Journal: Int J Geriatr Psychiatry Date: 2015-08-13 Impact factor: 3.485
Authors: Denise D Correa; Lisa M DeAngelis; Weiji Shi; Howard T Thaler; Michael Lin; Lauren E Abrey Journal: J Neurooncol Date: 2006-07-19 Impact factor: 4.130
Authors: Melissa L Bondy; Michael E Scheurer; Beatrice Malmer; Jill S Barnholtz-Sloan; Faith G Davis; Dora Il'yasova; Carol Kruchko; Bridget J McCarthy; Preetha Rajaraman; Judith A Schwartzbaum; Siegal Sadetzki; Brigitte Schlehofer; Tarik Tihan; Joseph L Wiemels; Margaret Wrensch; Patricia A Buffler Journal: Cancer Date: 2008-10-01 Impact factor: 6.860
Authors: Christopher H Chapman; Tong Zhu; Mohamad Nazem-Zadeh; Yebin Tao; Henry A Buchtel; Christina I Tsien; Theodore S Lawrence; Yue Cao Journal: Radiother Oncol Date: 2016-07-11 Impact factor: 6.280
Authors: D Fuentes; J Contreras; J Yu; R He; E Castillo; R Castillo; T Guerrero Journal: Int J Comput Assist Radiol Surg Date: 2014-11-20 Impact factor: 2.924
Authors: Anna K Paulsson; Kevin P McMullen; Ann M Peiffer; William H Hinson; William T Kearns; Annette J Johnson; Glenn J Lesser; Thomas L Ellis; Stephen B Tatter; Waldemar Debinski; Edward G Shaw; Michael D Chan Journal: Am J Clin Oncol Date: 2014-04 Impact factor: 2.339